Sermorelin pediatric growth hormone deficiency: the approved indication, read as verifiable status.

The short version

Sermorelin's home ground is sermorelin pediatric growth hormone deficiency. Some children are short because their bodies do not release enough growth hormone. In the 1990s a prescription form of sermorelin was approved in the United States to help diagnose and treat that condition, and a multicenter trial showed daily injections roughly doubled how fast these children grew in the first year. The branded product was taken off the US market in 2008 for business reasons, not safety. This page walks through that approved use and the trials behind it, each tied to its source.

FDA approval and 2008 withdrawal

Sermorelin pediatric growth hormone deficiency is where the FDA approval lived. Sermorelin was approved as a prescription GHRH analog under NDA 020443 for evaluating and treating idiopathic growth hormone deficiency and short stature in children. The US branded product was then withdrawn from the market in 2008 for commercial reasons — a business decision, not a safety or efficacy finding.

This is the single most misstated fact about sermorelin. It is not banned and it was not pulled for harm; it is simply no longer sold as a branded product. It remains available through compounding pharmacies and is treated as a long-standing Category 1 bulk drug substance under FDA's interim Section 503A policy, with final guidance issued in January 2025. That status is distinct from other GH-axis peptides (such as ipamorelin, ibutamoren, and kisspeptin-10) reviewed by the Pharmacy Compounding Advisory Committee in October 2024 — sermorelin's standing should not be conflated with those.

The multicenter height-velocity trial

The anchor efficacy study is a multicenter trial of prepubertal growth-hormone-deficient children. Once-daily subcutaneous GHRH(1-29) accelerated linear growth: first-year height velocity rose from about 4.1 cm/year to roughly 7-8 cm/year, and it did so without excessive IGF-1 generation ^[1]. Dosing was subcutaneous at bedtime, aligning the signal with the body's natural nocturnal GH pulse during early slow-wave sleep. That the effect appeared without runaway IGF-1 is consistent with sermorelin's upstream, feedback-preserving mechanism — it nudges the pituitary rather than flooding the system with external hormone.

Supporting pediatric studies

The pediatric record is broader than the single registration trial. Seven children with significant idiopathic short stature (height SD score -2.5 to -3.5) and normal GH levels received GHRH(1-29) at 30 mcg/kg/day; treatment stopped in two non-responders at 12 months and continued for 24 months in the other five, showing some such patients grow well during the first two years of GHRH treatment ^[8]. Eleven short children with normal GH given GRF(1-29)NH2 at 5 mcg/kg subcutaneously each evening for 6 months all increased growth velocity, even though 24-hour GH profiles and IGF-1 increments did not change significantly ^[10]. And in children given an intravenous GHRH(1-29NH2) bolus, idiopathic-short-stature children showed large GH responses while GH-insufficient children showed blunted ones ^[9] — the two groups separated cleanly.

Diagnostic use: the GHRH stimulation test

Before treatment, sermorelin had a diagnostic role. A single intravenous GRF(1-29)NH2 bolus (commonly ~1 mcg/kg) was used to test the pituitary's GH reserve. In one series, normal-stature children reached a mean peak plasma GH of 80.31 ng/ml at 45 minutes, whereas idiopathic GH-deficient children peaked at a significantly lower 13.10 ng/ml; about 21% of GH-deficient patients showed a partial response interpreted as hypothalamic-origin deficiency ^[11]. The test thus did double duty — separating deficient from normal children and helping localize where in the GH axis the defect sat.

Why the pediatric record is the strongest part of the case

Of everything sermorelin has been studied for, the pediatric indication is the only one that reached formal FDA approval, and it is the part of the record with prospective, controlled, multi-year human outcome data. That matters for reading the rest. The adult "anti-aging" and body-composition claims that dominate the marketing rest on a much thinner base — short studies, surrogate endpoints, and inferences borrowed from the related analog tesamorelin — and an Annals of Internal Medicine editorial judged growth-hormone-secretagogue use for aging "not yet ready for prime time." The pediatric data do not transfer to healthy adults: a growth signal in a GH-deficient child is not evidence of benefit in an adult with a normal GH axis. The honest summary is that sermorelin's best evidence is also its narrowest — the approved indication it is no longer branded for.

What is sermorelin used for?

Sermorelin was FDA-approved (as a prescription GHRH analog, NDA 020443) for evaluating and treating idiopathic growth hormone deficiency and short stature in children, and it has been studied in adult GH-axis research — aging, cognition, sleep, and body composition. It was withdrawn from the US market in 2008 for commercial reasons and is now compounded. The pediatric indication is the documented, formerly-approved use ^[1].

Why was the branded sermorelin product discontinued?

The branded US sermorelin product (NDA 020443) was withdrawn from the market in 2008 for commercial reasons — not because of any safety or efficacy problem. Sermorelin remains available through compounding pharmacies and is treated as a Category 1 bulk drug substance under FDA's interim Section 503A policy. The discontinuation was a market decision about a product, not a verdict on the molecule.